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PROBLEM IDENTIFICATION AND
DESCRIPTION OF NEED
• There are several buprenorphine providers at EMMC’s Center for Family Medicine serving
the greater Bangor region, an area of substantial opiate use
• Among the patient population of outpatient buprenorphine users, both locally and nationally,
there are high rates of relapse (32%) 1

• In order to decrease relapse rates, it is imperative to conduct a baseline review of the current
buprenorphine population to identify specific types of patients who are at higher risk of
relapse
• By understanding the barriers to recovery, one can apply an intervention to the current
program, targeting this local demographic more effectively
• Future researchers can also use this baseline data as a control group, comparing the
intervention to the current treatment model (medication, individual therapy, group therapy)
2

PUBLIC HEALTH COST OF OPIATES IN MAINE
• Deadly Crisis
• Deaths from heroin overdoses increased from 7 in
2010 to 57 last year (2/3 between ages 20-40) 2
• Overdose deaths involving prescription drugs (e.g.
methadone, oxycodone, and benzodiazepines)
tripled from 51 in 2000 to 161 in 2010 3
• 95% of overdose deaths in Maine involved
prescription drugs in 2010 3

• High Rehab Demand

• Availability Increasing
• Heroin is more available, purity levels are
increased, street prices have dropped resulting in
dramatic increase in heroin addiction across the
nation 5

• Burden on Crime Enforcement
• In 2012, heroin accounted for 8 percent of the
caseload for Maine’s Drug Crimes Task Force; last
year, it jumped to 32 percent 2

• As of 2012, prescription opioids are the second most
common substance for which treatment is sought,
• Prices Dropping
3
just behind alcohol
• Today in Maine, a single tablet of oxycodone often
• 11,518 individuals sought rehab in Maine - 37.19%
costs $50; addicts can find a single-dose packet of
4
reported opioids as primary substance
heroin for as little as $10 2

• Ballooning Costs

3

• Estimated cost of substance abuse in Maine is $1.18
billion, $888 for each Maine resident (crime, deaths,
and medical care) 4

METHODOLOGY AND INTERVENTION
• Goal
• Develop a descriptive summary of current CFM buprenorphine users to understand the
barriers to recovery in the greater Bangor area
• Methodology
• Retrospective chart review of all
buprenorphine patients who have filled out
both the Recovery Rating Scale and Opiate
Craving Survey (n = 32) within the last year
(July 2014-July 2015)
• Summarize key demographic information
• Report average scores on Recovery Rating
Scale and Opiate Craving Survey
• Trend those patients who have filled out >2
Opiate Craving Surveys

• Conduct interviews with community experts
and patients on buprenorphine use
4

• Intervention
• Presentation of data to the Social Workers and
buprenorphine providers at EMMC’s CFM
• Share suggestions for program interventions
based on identified barriers to recovery and
community/patient perspectives

• Compile baseline data into excel format for
future data manipulation and to allow for use
as a control group in future studies
• i.e. comparing future intervention to the
current treatment model

COMMUNITY PERSPECTIVE
Matt Nutt, LCSW – Opiate Addiction Counselor

Jessica Bloom-Foster, MD – Buprenorphine Provider

Center for Family Medicine, Bangor, ME

Center for Family Medicine, Bangor, ME

• Public Health Concerns

• Current Relapse Rates at CFM

• “Opiate dependence, when untreated, can result in overdose,
medical complications, lack of healthcare coverage, lack of
medical /dental care management, decrease in self-worth,
decrease population in the workforce, […] and increased burden
on public welfare resources.”

• Treatment to Fight Crime
• “Many long term users, dependent, eventually end up out of the
workforce and in trouble […]. Opioid based replacement
treatment are shown to decrease crime rates where treatment is
available.”

• Identifying Comorbid Conditions
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• “I initially looked at 31 newly enrolled patients in the
buprenorphine treatment program from January to June
of 2014 and followed their charts to see who met
definition of relapse.What we found mimicked the
general population of buprenorphine users in that 32%
met criteria for relapse.

• Intervention Ideas
• “Based on anecdotal evidence in our buprenorphine
population, I think there is room for a study on the role of
mindfulness in recovery. I envision the providers hosting
a brief educational session on mindfulness at first intake
and providing patients with audio files to practice their
mindfulness tools once a day.”

• “[…] there is a higher incidence of Hep C/HIV in the IV using
community. When I was working at Acadia’s Narcotic Treatment
Program, we had a 50% Hep C positive rate with a clinic treatment • A Role for Providers
caseload of approximately 700 clients (mid to late
• “We hope to ultimately show that primary care docs can
2000s). Untreated Hep C/HIV often leads to very costly treatment
teach meaningful tools like mindfulness to patients in
later.” I believe screening these individuals and treating them
recovery programs and that these tools can make a
during visits could drastically decrease costs and increase
substantial impact on their recovery time.”
recovery rates.

COMMUNITY PERSPECTIVE
Paula Codrington, LCSW – Opiate Addiction Counselor

Anonymous Patient on Buprenorphine

Center for Family Medicine, Bangor, ME

Center for Family Medicine, Bangor, ME

• Psychological Hurdles
• “Addicts in recovery will take a few steps forward and then
one back - relapse is part of the process so it should be
considered a challenge not a failure”
• “Often people will get stuck and use the idea that they failed
as the reason to keep using and not keep trying to take steps
forward”
• “Black and white thinking (all or nothing perspective) makes
it more difficult to maintain a path towards recovery”

• Importance of Self Awareness
• “If you are not aware of what is going on in your head and
heart and your patterns you can’t make change, and without
being aware of the patterns, you can’t get past the hurdles to
recovery”
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• On Challenges
• “Other’s people influence [is the hardest part]. My neighbor
asked me to help her shoot up heroin and it brought me right
back to the feelings I would have before I used. The sweats,
anxiety…”

• On Coping Skills
• “I think of my family, husband, animals. I try to keep busy. I used
to be really sick and that is why I used. I am feeling better health
wise now that I am on [buprenorphine] so I don’t feel the need to
use. [Also] being around others, having a support system is
important. I have learned more to stay away from negative
people, like my neighbor. It’s important to change social
situations.”

• On Group Therapy
• “Group is good to learn [coping] skills. Group makes me feel
better and I was anxious about that because I have bad anxiety
and didn’t think I would like group. Music meditation, we did that
one, and I liked that. Music is important to me. Doing crafts or
coloring which we do sometimes is good to help relieve stress,
but it doesn’t [always] last. It’s like a band aid.”

RESULTS

Patient Demographics

Average Recovery Rating Scores

Comorbid Mental Health Dx
• Sex of Patient (n=32)
• Male = 7 (22%)

None, 7

4

Anxiety,
17

• Female= 25 (78%)
• Pregnant = 21 (84%)
• Not pregnant = 4 (16%)

Score

Other, 4

RRS Questions (1)

5

3.53
2.94

3

0

ADHD,
7

Health

Stress Exercise Eating

5

PTSD, 9

Both, 7
(23%)

MDD,
14

3.84

3.88

3.97

3.63

4.03

3.84

3
2
1

Drug of Choice
(n=31)

0

D&A

Heroin, 6
(19%)

Triggers Dose

Support Coping Success

Fxn

RRS Questions (3)

• Previous Recovery Attempts (n=32)

5

• No = 13 (41%)

4.57

4.57

4.71

4.61

Therapuetic

Goals

Approach

Overall

4

Score

• Yes = 19 (59%)
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4.13

4

Score

Bipolar,
8

• Yes = 25 (78%)

• Key: Pink = Barriers to Recovery

Sleep Purpose Social

RRS Questions (2)

• No = 7 (22%)

• Average ACE Score = 5.85 (n=15)

3.03

1

• Comorbid Mental Health Dx (n=32)

• Multiple = 17 (68%)

3.28

2

• Average age = 29.56 (n= 32)

• Age at 1st opiate use = 19.48
(n=31)

3.25

3.88

3.44

Pills, 18
(58%)

3
2
1
0

RESULTS
Opiate Craving Trends in Patients Who Completed >2 Forms (n = 6)

1.53

1.91

Q1

Q2

1.22

1.56

1.5

Q3

Q4

Q5

Score

5
4
3
2
1
0

Form 2

Q1

Q2

6
5
4
3
2
1
0

Q3

Average

Max

%

RRS 1

23.34

35

67%

RRS 2

27.31

35

78%

RRS 3

18.46

20

92%

OCS

7.72

25

31%

6
5
4
3
2
1
0

Q5

Form 1
Form 2

Q2

Total Average Scores Per Scale
Scale

Q4

6
5
4
3
2
1
0

Patient 38

Q1

Q3

Q4

Q5

Form 1
Form 2

Q2

Q3

Q4

Form 1
Form 2

Q1

Q2

Q3

Q4

Q5

Patient 59
Form 1
Form 2

Q2

Q3

Q4

Q5

Patient 76

6
5
4
3
2
1
0
Q1

Patient 57

Q1

Patient 48

Score

Score

.
Average Opiate Craving Scores

Form 1

Score

• Very high RRS 3 % (orange)

Patient 25

6
5
4
3
2
1
0

Q5

Score

• On average, low craving scores for
patients on medication (pink)

Score

• 3 patients with complete decreased
craving scores (purple stars)

Score

Evidence of Program Success

6
5
4
3
2
1
0

Form 1
Form 2
Form 3
Q1

Q2

Q3

Q4

Q5
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EVALUATION OF EFFECTIVENESS AND
LIMITATIONS
• Effectiveness

• Limitations

• Our first aim was to
summarize the data set - in
this regard we succeeded

• Due to the relatively recent distribution of the Opiate Craving Scale,
the retrospective chart review yielded a small sample size with a
large standard deviation across all measures

• Given the obstacles we
encountered with data
integrity, both the LICSWs
and providers were pleased
with our findings and will use
our recommendations for
future projects

• Our evaluation relied on self reported data from a questionnaire,
making it difficult to validate patient responses

• The information compiled for
future data manipulation was
organized in excel and
distributed to the team (see
attached)
7

• In order to find any significance in outcomes of treatment, providers will
likely need to greatly increase the patient population to include all ~ 200
buprenorphine users in the practice

• Poor self-esteem, a low level of education, and legal problems are
common in opiate users and interfere with self-reporting 6
• Corroboration of the data with a second questionnaire, or variations on
the same questions, may help increase validity and assess reliability

• The time interval between initial intake and survey distribution was
not standardized and often not recorded
• Future studies need to standardize specific time stamps for data collection
in order to yield significance – analyzing points in time will allow for
better trending and more useful data analysis

RECOMMENDATIONS
Barriers to Recovery
• Females make up 78% of the patient population, 84% of whom were pregnant at intake
• Social stigma, guilt and shame of ongoing drug addiction during pregnancy may pressure the woman into attempting to quit using
opiates on her own or hiding the problem until delivery 6
• The partner’s continued use of opiates can be an insurmountable problem because the woman may be caught in between the need
for emotional/financial support with the continued temptation to relapse 6
• Treatment compliance and pregnancy outcomes are improved when addiction and obstetrical care are delivered at the same
location 6

• Recommendation: Key in on these considerations while treating pregnant women in order to decrease relapse rates

• 78% of patients had a comorbid mental illness, and of those, 68% had a diagnosis of > 2 mental illnesses
• Psychiatric disorders are associated with increased physical symptoms such as pain and are associated with increased opioid use 7
• Recommendation: Imperative for providers and social workers to focus on treating mental health concurrently

• Average scores for RRS1 (67%) and RRS2 (78%) could be improved across patient population
• On RRS 1, particularly low scores included answers to questions on stress management, daily physical activity, healthy eating, sleep
hygiene, and social support improvement
• On RRS 2, particularly low scores included answers to questions on triggers and healthy coping skills

• Recommendation: Future interventions should include a focus on stress management, physical activity, healthy eating, sleep
hygiene, social support, triggers and coping skills
•
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e.g. a mindfulness program like the one suggested by Dr. Bloom Foster could be one key step toward decreasing relapse rates

RECOMMENDATIONS
Evidence of Success with Current Program
• Very high patient satisfaction with therapy as measured by RRS3 (92%)
• Overall low average on self-reported Opiate Craving Surveys (31%)
•

Recommendation: Continue to provide therapy in combination with buprenorphine as much as possible for the best
opportunity at a successful recovery

Additional Ideas and Recommendations for Future Investigation
• Standardize the intake process for all patients receiving buprenorphine, including specific times throughout the treatment at
which patients receive the RRS and OCS questionnaires
• Per Matthew Nutt’s suggestion, investigate the rates of HCV and HIV comorbidities in order to understand how these
patients can be better screened and treated
• Looking at the small sample size of trending OCS responses (patients 25, 38, 48, 57, 59, 76), identify what factors make
certain patients more successful via correlation with their RRS and demographic data
• Once local barriers to recovery are fully understood, one could project how well a patient will do in treatment and how
likely he or she is to relapse

• Focus investigations on those with previous recovery attempts (59%) and ultimately failed to understand what may have
occurred and individualize treatment based on those prior obstacles
• Per Paula Codrington’s suggestion, in each patient encounter, focus on psychological hurdles such as all-or-nothing thinking
to help patients better understand the progression of recovery
8b
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